Abstract 354P
Background
Colorectal cancer (CRC) presents among leading causes of death and oligometastases presents a dilemma in treatment options. If treated, CRC with oligometastases can present improved survival. Our study aims to evaluate predictive factors associated with survival when treated with stereotactic body radiation therapy (SBRT).
Methods
A total of 125 metastases in 50 patients were treated with SBRT. Oligometastases was defined as up to 5 lesions in lung in proven primary histopathology of CRC. Survival outcomes in terms of local control (LC), progression free survival (PFS), and overall survival (OS) were assessed along with association of various predictive factors associated with survival outcomes.
Results
Among the 50 patients, Lung was the most common site of metastases (52.5%), followed by liver (34%). Thirty patients had received prior systemic therapy in form of chemotherapy. Median follow-up time was 24 months (6-84 months). The LC rates at 1, 3 and 5 years were 96%, 72% and 69%, respectively. The first site of failure was local only in 20%, distant only in 34%, and local and distant in 16% of the patients. Median PFS was 9.8 months. The overall survival at 1, 3 and 5 years was 87.2%, 62.3%, and 41.4%, respectively. On assessment of predictive factors, metastases more than 3 cm (p =0.012), presence of non-lung metastases (p < 0.001) and progression of treated metastases (p = 0.021) predicted for worse overall survival.Multiple lung metastases and synchronous oligometastatic disease were significantly associated with worse PFS and worse metastases-free survival. On toxicity assessment, no Grade 3 toxicities were found in the cohort.
Conclusions
Stereotactic body radiation therapy presents longer survival in oligometastases in CRC and is a proven treatment modality. Treatment and control of oligometastases predicts for improved overall survival. Further prospective cohorts would better evaluate effective fractionation for patients with oligometastatic CRC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
339TiP - PACIFIC-5: Phase III study of durvalumab after either concurrent or sequential chemoradiotherapy (CRT) in patients with stage III NSCLC
Presenter: Yi-Long Wu
Session: Poster display session
Resources:
Abstract
340TiP - A multicenter, randomized, controlled, phase II trial exploring adjuvant combined therapy of apatinib and SHR-1210 (anti-PD-1), in patients with hepatocellular carcinoma at high risk of recurrence after radical resection
Presenter: Shida Yan
Session: Poster display session
Resources:
Abstract
347P - Relationship between modified surgical margin and prognosis of cutaneous squamous cell carcinoma
Presenter: Yukiko Teramoto
Session: Poster display session
Resources:
Abstract
348P - Malignant melanoma: A study of clinical profiles and treatment outcomes in Indian patients
Presenter: Sorun Shishak
Session: Poster display session
Resources:
Abstract
349P - Flavonoids from ethanol extracts of euphorbia hirta inhibit melanoma growth and metastatic potential
Presenter: Shubhra Mishra
Session: Poster display session
Resources:
Abstract
350P - Low-dose cisplatin and 5-fluorouracil combined concurrent chemoradiotherapy for unresectable cutaneous squamous cell carcinoma: Analysis of 23 cases
Presenter: Azusa Hiura
Session: Poster display session
Resources:
Abstract
353P - A prediction model for the intents regarding life-sustaining treatment decisions in patients with terminal cancer
Presenter: Yoonsun Kim
Session: Poster display session
Resources:
Abstract
355P - Cost analysis and overview of single versus multiple fraction palliative radiotherapy for painful bone metastasis
Presenter: Vinodhkumar Selvaraj
Session: Poster display session
Resources:
Abstract
356P - Observational study on role of crude cannabis in pain control and quality of life in terminally ill cancer patients: An Indian perspective
Presenter: Vidyasagar Dusi
Session: Poster display session
Resources:
Abstract
357P - Application of multi-modal approach to palliation in end of life head and neck cancer pain
Presenter: Srujana Joga
Session: Poster display session
Resources:
Abstract